Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

The demand for weight loss medications are on the rise, and now, “natural” GLP-1s are being marketed to help you lose weight.

The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...